NEW YORK, Jan. 27, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of XBiotech Inc. (“XBiotech”) (Nasdaq:XBIT) between April 15, 2015 and November 23, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Western District of Texas. If you purchased or otherwise acquired XBiotech securities between April 15, 2015 and November 23, 2015, your rights may be affected by this action. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
According to the complaint, the Company made materially false and misleading statements to investors and/or failed to disclose that: (1) a fewer number of per protocol patients were available for primary endpoint evaluation in the Phase III Study; (2) the data from 72 patients of the Phase III Study was compromised; (3) XBiotech did not adequately sample patients to accommodate data loss; and (4) as a result of not properly sampling patients, the Phase III Study would have reduced statistical power to demonstrate the proposed outcome.
If you suffered a loss in XBiotech you have until February 1, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 



